Screening platform for identifying estrogen modulators
A screening platform that uses in vitro assays to identify potential estrogen modulators from natural and synthetic sources. The platform aims to aid in the discovery of treatments for hormone-related cancers by testing the impact on aromatase and androgen receptors.
Overview
The screening platform developed by Ohio State University is designed to identify potential estrogen modulators through a series of in vitro assays. This technology aims to uncover new treatments for hormone-related cancers such as breast and prostate cancer by evaluating the impact of samples on estrogen synthesis pathways. The platform leverages extensive laboratory experience in testing natural and synthetic compounds, providing a robust tool for drug discovery.
Technical specifications
The platform uses a stepwise approach to screen samples against aromatase, estrogen, and androgen in vitro assays. Initially, samples are tested in an aromatase assay to identify inhibitors that could prevent the conversion of androgens to estrogens. Active samples are further evaluated in the Androgen Receptor assay using whole cells, assessing their selectivity by measuring endogenous or overexpressed androgen receptor levels. Subsequently, the same samples undergo testing in a human estrogen assay. Samples that show significant activity are further tested across multiple concentrations to determine their IC50 values through non-linear regression analysis.
Technology readiness level
This screening platform is currently at Technology Readiness Level 3, indicating that it is in the experimental proof-of-concept stage. The platform has been validated in laboratory settings and is ready for further development and optimization.
About The Ohio State University
The Ohio State University is a comprehensive public land‑grant research university in Columbus, serving one of the nation’s largest student populations and a broad research enterprise. Industry partners engage through an integrated academic medical center for clinical translation, a campus‑adjacent innovation district for co‑located projects, and a statewide extension network that pilots solutions across Ohio. Corporate engagement provides a single front door for sponsored research, talent pipelines, and streamlined agreements. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, USDA, DoD, and NASA. A dedicated technology transfer office and venture support help protect IP, license technologies, and launch startups.
delivered to your inbox.